Close Menu

NEW YORK (360Dx) – Vermillion reported today a 44 percent rise in first quarter revenues.

For the three months ended March 31, the Austin, Texas-based cancer diagnostics firm said that total revenues rose to $726,000 from $505,000 in the year-ago quarter.

Product revenues were $678,000, up from $505,000 in Q1 2016. Service revenues were $48,000. The company posted no service revenues in the year-ago quarter as it had not yet launched its Aspira IVD service business.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.